关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
" g6 r% ^5 R5 q  K' B2 l8 y: y    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。

( n; j- S3 Y4 v作者：来自澳大利亚
. q7 U$ t. w+ j- h: j来源：Haematologica. 2011.8.9.
: z. a. `+ r5 c( Z1 t) @1 e6 \- YDear Group,
% Y) J0 }: t1 E" D8 u
Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
) [: s, f; W3 `! w" I% Ytherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
3 b* Q* ]# K8 v8 Ndoes spike up the immune system so I hope more reports come out on this issue.
7 H; f" j4 L/ ?( r8 [5 `" @
' g* j! l2 S$ I) L: b! N! JThe remarkable news about Sprycel cessation is that all 3 patients had failed
2 ~2 |; `9 @. ?( w! W$ X! s8 CGleevec and Sprycel was their second TKI so they had resistant disease. This is
. W7 E+ ?5 a2 c7 n# Q/ v$ L% z" Gdifferent from the stopping Gleevec trial in France which only targets patients
/ i' D& e# y. m7 ywho have done well on Gleevec.
$ Y" s: g9 y; G+ Q" B
Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.

Best Wishes,
9 R& `# f6 W6 ~9 f, l/ IAnjana

( u, ~0 c3 f' H' x6 M

5 y3 m& O: A0 N$ m" eHaematologica. 2011 Aug 9. [Epub ahead of print]
* W. \2 o' y" w2 pDurable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
3 u$ P1 k8 @& C5 q- ]2 GRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
- Z+ N; F. \5 m' D) c) I, W& ~Adelaide, Australia;
( E- T3 b5 x. u! X. `* U
5 q0 j' B& U: B& i7 A! }* LAbstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
0 R) H! R# D/ W$ o& ~durable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
4 ]5 f$ k2 M0 a& mresponse have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
2 z: \  K' d. c& ycomplete molecular response more than 12 months after stopping dasatinib. In
7 \: t" G  k! o9 q  rthese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
) \. C3 X1 D6 z( P! kshow that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
1 i$ i; L, h, R7 h5 O+ U: J! uthe emergence of clonal T cell populations, were observed both in one patient
* G0 Q  \& i" ]who relapsed and in one patient in remission. Our results suggest that the
7 D$ V( x* H: fcharacteristics of complete molecular response on dasatinib treatment may be
+ T1 F+ ^% k- m9 y3 V4 xsimilar to that achieved with imatinib, at least in patients with adverse
) y: h; d# b' D/ V- q3 _disease features.
8 C3 S( I6 ~" l

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
& M/ x9 L/ Z$ J+ h# M$ {' f3 V    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
0 W1 ?8 d# {/ _- H/ o) P1 s1 ?1 [
作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事